Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...

Cingulate, Inc. (NASDAQ:CING) reported third quarter 2025 results on November 13 th, 2025. No revenues were recorded and operating expense totaled $6.0 million. The new drug application (NDA) to the ...